FDA Approves Pfizer's TUKYSA as Front-Line Maintenance for HER2+ Metastatic Breast Cancer
PFE sits 19% above its 52-week low of $23.62 on light trading volume (0.3× avg).
Summary
The FDA approved TUKYSA (tucatinib) in combination with trastuzumab and pertuzumab as maintenance therapy for adults with unresectable locally advanced or metastatic HER2+ breast cancer following induction treatment. This expands TUKYSA from second-line to front-line use, creating a chemotherapy-free option that delays disease progression. In the pivotal HER2CLIMB-05 trial, the regimen reduced the risk of disease progression or death by 35.9% (HR 0.64, p<0.0001) and extended median progression-free survival by 8.6 months (24.9 vs 16.3 months). The approval carries a boxed warning for severe hepatotoxicity, including one fatal case, which may temper commercial uptake. This is a meaningful label expansion for a key oncology asset and follows Pfizer's recent pipeline momentum, including the Metsera acquisition and positive tilrekimig data.
At the time of this announcement, PFE was trading at $28.07 on NYSE in the Life Sciences sector, with a market capitalization of approximately $160B. The 52-week trading range was $23.62 to $29.21. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.